Ectopic P granules protein 5 homolog (EPG5)

Homo sapiens — UniProt Q9HCE0

Gene: EPG5Homo sapiensSwissProt reviewed

Data last refreshed: 2026-04-18 (UniProt release unknown)

Key facts

Ectopic P granules protein 5 homolog (EPG5) is a protein from Homo sapiens identified by UniProt accession Q9HCE0, 2579 residues long. MolForge cross-references it against 0 known binders and 190 disease associations.

UniProt accession: Q9HCE0; gene symbol EPG5.
Organism: Homo sapiens.
Length: 2579 amino acids.
Top disease associations (Open Targets): Vici syndrome, neurodegenerative disease and genetic disorder.
3D structure: AlphaFold model available.

Target properties

Protein name	Ectopic P granules protein 5 homolog
UniProt accession	Q9HCE0
Gene	EPG5
Organism	Homo sapiens
Length	2579 residues
Molecular weight	—
EC numbers	—
Target class	—
Subcellular location	—
Keywords	—

Druggability

Target tractability assessment (Open Targets + pocket analysis). No approved drug

Druggability tier	MEDIUM
Druggability score	—
Pocket score	—
Max clinical phase	—

Disease associations (190)

Diseases linked to this target (Open Targets).

Vici syndrome · score 0.86
neurodegenerative disease · score 0.53
genetic disorder · score 0.51
syndromic retinitis pigmentosa · score 0.40
hair colour measurement · score 0.27
mean corpuscular hemoglobin · score 0.24
hair color · score 0.21
Microcephaly · score 0.15
Global developmental delay · score 0.11
platelet count · score 0.09

3D Structure (1)

Experimental (PDB) and predicted (AlphaFold) structures for this protein.

Structure	Source	Method	Mean pLDDT	Resolution (Å)
AF-Q9HCE0-F1	alphafold	PREDICTED	73.47	—

Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9HCE0.

Amino-acid sequence (2579 residues)

MAEAVKPQRR AKAKASRTKT KEKKKYETPQ REESSEVSLP KTSREQEIPS LACEFKGDHL KVVTDSQLQD DASGQNESEM FDVPLTSLTI SNEESLTCNT EPPKEGGEAR PCVGDSAVTP KVHPGDNVGT KVETPKNFTE VEENMSVQGG LSESAPQSNF SYTQPAMENI QVRETQNSKE DKQGLVCSSE VPQNVGLQSS CPAKHGFQTP RVKKLYPQLP AEIAGEAPAL VAVKPLLRSE RLYPELPSQL ELVPFTKEQL KILEPGSWLE NVESYLEEFD SMAHQDRHEF YELLLNYSRC RKQLLLAEAE LLTLTSDCQN AKSRLWQFKE EQMSVQGICA DQVKVFSYHR YQRVEMNENA LVELKKLFDA KSEHLHQTLA LHSYTSVLSR LQVESYIYAL LSSSAVLRSS AIHQQGRASK QTESIPSDLC QLKECISVLF MFTRRVNEDT QFHDDILLWL QKLVSVLQRV GCPGDHLFLL NHILRCPAGV SKWAVPFIQI KVLHNPSGVF HFMQSLALLM SPVKNRAEFM CHMKPSERKP SSSGPGSGTW TLVDEGGEED EDPETSWILL NEDDLVTILA QFPFHELFQH LLGFKAKGDY LPETTRPQEM MKIFAFANSL VELLAVGLET FNRARYRQFV KRIGYMIRMT LGYVSDHWAQ YVSHNQGSGL AQQPYSMEKL QVEFDELFLR AVLHVLKAKR LGIWLFMSEM PFGTLSVQML WKLFYLMHQV ESENLQQLSS SLQPAQCKQQ LQDPEHFTNF EKCLSSMNSS EEICLLTTFA QMAQARRTNV DEDFIKIIVL EIYEVSYVTL STRETFSKVG RELLGTITAV HPEIISVLLD RVQETIDQVG MVSLYLFKEL PLYLWQPSAS EIAVIRDWLL NYNLTVVKNK LACVILEGLN WGFAKQATLH LDQAVHAEVA LMVLEAYQKY LAQKPYAGIL SESMKQVSYL ASIVRYGETP ETSFNQWAWN LILRLKLHKN DYGIQPNCPA VPFSVTVPDM TESPTFHPLL KAVKAGMPIG CYLALSMTAV GHSIEKFCAE GIPLLGILVQ SRHLRTVVHV LDKILPLFYP CQYYLLKNEQ FLSHLLLFLH LDSGVPQGVT QQVTHKVAQH LTGASHGDNV KLLNSMIQAH ISVSTQPNEV GPVAVLEFWV QALISQHLWY REQPILFLMD HLCKAAFQLM QEDCIQKLLY QQHKNALGYH CDRSLLSSLV SWIVAGNITP SFVEGLATPT QVWFAWTVLN MESIFEEDSQ LRRVIEGELV INSAFTPDQA LKKAQTQLKL PIVPSLQRLL IYRWAHQALV TPSDHPLLPL IWQKFFLLYL HRPGPQYGLP IDGCIGRRFF QSPAHINLLK EMKRRLTEVA DFHHAASKAL RVPAEGSEGL PESHSGTPGY LTSPELHKEL VRLFNVYILW LEDENFQKGD TYIPSLPKHY DIHRLAKVMQ NQQDLWMEYL NMERIYHEFQ ETVGLWTQAK LESHSTPCSL SVQLDFTDPL LAKERVLSNL RKHEAPQPPL ALHPTKPPVP VISSAVLLSQ KDATQLVCTD LNLLQQQART AALRESQQVA LDGELLDTMP KQYVNREEQT TLHLECRGSS GKKCQGAAVV TVQFEGMHKN EAISQQLHVL RKEVKQLQAE AAKPPSLNIV EAAVHAENLI TALVNAYKLQ PTPGIQKVGI SLFFTIVDYV SDETQRHPPT RQFFTSCIEI LGQVFISGIK SECRKVLETI LKNSRLCSLL SPFFTPNAAP AEFIQLYEQV VKFLSEDNSD MIFMLLTKFD LKQWLSATKP PLSDRTRLLE SIHLALTAWG LEPDEDILMP FNLFCKHWTY LLLYQFPDQY SDILRLLMQS SAEQLLSPEC WKATLRALGC CAPSCQQGAA STEGAVLPSS SDALLSDKQV METIQWLSDF FYKLRLSKMD FKSFGLFSKW SPYMADVKTF LGYLVKRLID LEMTCLAQDP TASRKTVLKS LHSVIIQLFK PWILVLEDNE SSQQRHYPWL ESDTVVASSI VQLFTDCIDS LHESFKDKLL PGDAGALWLH LMHYCEACTA PKMPEFILYA FHSTYRKLPW KDLHPDQMLM EAFFKVERGS PKSCFLFLGS VLCEVNWVSV LSDAWNSSPH PETRSMIVCL LFMMILLAKE VQLVDQTDSP LLSLLGQTSS LSWHLVDIVS YQSVLSYFSS HYPPSIILAK ESYAELIMKL LKVSAGLSIP TDSQKHLDAV PKCQAFTHQM VQFLSTLEQN GKITLAVLEQ EMSKLLDDII VFNPPDMDSQ TRHMALSSLF MEVLMMMNNA TIPTAEFLRG SIRTWIGQKM HGLVVLPLLT AACQSLASVR HMAETTEACI TAYFKESPLN QNSGWGPILV SLQVPELTME EFLQECLTLG SYLTLYVYLL QCLNSEQTLR NEMKVLLILS KWLEQVYPSS VEEEAKLFLW WHQVLQLSLI QTEQNDSVLT ESVIRILLLV QSRQNLVAEE RLSSGILGAI GFGRKSPLSN RFRVVARSMA AFLSVQVPME DQIRLRPGSE LHLTPKAQQA LNALESMASS KQYVEYQDQI LQATQFIRHP GHCLQDGKSF LALLVNCLYP EVHYLDHIR

External references

UniProt AlphaFold QuickGO RCSB PDB GeneCards

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

Which diseases are associated with EPG5?

The strongest Open Targets associations for EPG5 are Vici syndrome, neurodegenerative disease, genetic disorder, syndromic retinitis pigmentosa and hair colour measurement.

How long is the EPG5 protein?

The Homo sapiens EPG5 protein (UniProt Q9HCE0) is 2579 amino acids long.

Browse: Targets: E · all protein targets A–Z · drugs A–Z.

Sources

UniProtKB Q9HCE0 — name, gene, function, sequence, keywords (CC BY 4.0)
AlphaFold DB Q9HCE0 — predicted 3D structure (CC BY 4.0)
Open Targets Platform — disease associations and tractability (CC0)

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.